Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

@article{Tegeder2006CardiovascularRW,
  title={Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?},
  author={Irmgard Tegeder and Gerd Geisslinger},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2006},
  volume={373},
  pages={1-17}
}
Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Clinical Pharmacology and Cardiovascular Safety of Naproxen

  • American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Chapter 4 – Pharmacology

VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 173 REFERENCES

Similar Papers

Loading similar papers…